Egrifta (Tesamorelin) Switching Protocols: From/To Other Drugs in Class
HealthRX.com
No switching protocol exists for tesamorelin
Key numbers
- 1.4 mgEgrifta SV dose, given once daily under the skin of the abdomenSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- +16% to +22%Visceral fat gain in weeks 26 to 52 after switching to placebo; continuing tesamorelin gave 0% to -5%Source: dailymed.nlm.nih.gov, as cited Nov 7, 2026
- 15.2%Visceral fat change at 26 weeks on tesamorelin, versus a 5.0% rise on placeboSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
At a glance
- Approved / November 10, 2010, for excess abdominal fat in HIV-infected adults with lipodystrophy [3][1]
- Current doses / Egrifta SV 1.4 mg or Egrifta WR 1.28 mg once daily, subcutaneously into the abdomen [1][2]
- Formulations / Egrifta SV and Egrifta WR are not substitutable [2]
- Half-life / about 8 minutes (SV 1.4 mg) and about 11 minutes (WR 1.28 mg) in healthy subjects [1][2]
- On stopping / visceral fat rises again when tesamorelin is replaced by placebo [1]
Is there a switching protocol?
The trials described in the labels and in the published literature compared tesamorelin with placebo, or continued tesamorelin with placebo after 26 weeks [1][4][5]. None of the data here tested a switch from tesamorelin to another GHRH analogue, a GH-releasing peptide, somatropin or a GLP-1 receptor agonist, or the reverse.
What the Egrifta labels say
Egrifta was first approved on November 10, 2010 [3]. Two formulations are current: Egrifta SV at 1.4 mg (0.35 mL of the reconstituted solution) and Egrifta WR at 1.28 mg (0.16 mL), each injected once daily under the skin of the abdomen with sites rotated [1][2]. The WR label states that the two are not substitutable [2]. Tesamorelin binds and stimulates human GRF receptors with potency similar to the body's own GRF, prompting pituitary somatotroph cells to release endogenous growth hormone, which raises IGF-1 and IGFBP-3 [1]. The peptide clears quickly: mean elimination half-life was about 8 minutes after a 1.4 mg Egrifta SV dose and about 11 minutes after a 1.28 mg Egrifta WR dose in healthy subjects [1][2]. That is a pharmacokinetic measurement, not a washout recommendation.
Contraindications and monitoring
The Egrifta labels list tesamorelin as contraindicated with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [1][2]. The label says any preexisting malignancy should be inactive and its treatment complete before starting, and that tesamorelin should be discontinued if malignancy recurs [1].
IGF-1 is a labeled safety signal: among patients treated for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3 SDS; among those treated for 52 weeks, 34% and 23% [1]. The label says to monitor IGF-1 and to consider discontinuing for persistent elevations, for example above 3 SDS, particularly if the efficacy response is not robust [1]. HbA1c of 6.5% or higher from baseline to week 26 occurred in 5% of tesamorelin patients versus 1% on placebo (hazard ratio about 3.3, 95% CI 1.4 to 9.6) [1]. The label says to evaluate glucose before starting and monitor periodically, including for development or worsening of retinopathy in people with diabetes [1].
Interactions the label names
GH inhibits 11-beta-HSD1, the enzyme that converts cortisone to cortisol, so the label says patients on glucocorticoid replacement for hypoadrenalism may need higher maintenance or stress doses after starting tesamorelin; cortisone acetate and prednisone may be affected more than other steroids [1]. The label also says GH may alter clearance of drugs metabolized by CYP450 liver enzymes, including corticosteroids, sex steroids, anticonvulsants and cyclosporine, and advises monitoring [1].
If tesamorelin stops
From week 26 to week 52, patients re-randomized to placebo gained visceral fat (+16% to +22%), while those who continued tesamorelin ranged from 0% to -5% [1]. Those extension data describe what happened when patients switched from tesamorelin to placebo; they do not show what happens after switching to another drug [1][4]. In the 26-week, 412-patient study, visceral adipose tissue fell 15.2% on tesamorelin and rose 5.0% on placebo [5].
Check what you know
Question 1 of 4
Score: 0 right, 0 of 4 answered
Questions worth asking
Frequently asked questions
Do the Egrifta labels give a washout period before switching?
How fast does tesamorelin clear from the body?
What IGF-1 level does the label flag during tesamorelin therapy?
Does tesamorelin interact with HIV antiretroviral drugs?
What happens to visceral fat if tesamorelin is stopped?
References
Show all 5 referencesHide references
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Drugs@FDA: FDA-Approved Drugs.
- Falutz J, Potvin D, Mamputu JC, Assaad H, Zoltowska M, Michaud SE, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53(3):311-22.
- Falutz J, Allas S, Blot K, Potvin D, Kotler D, Somero M, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70.